

## Final Agenda

### MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

**Tuesday, April 15, 2025**

#### **8:00 Welcome & Introductions**

Dr. Keipp Talbot (ACIP Chair)  
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

#### **8:15 Mpox Vaccine**

Introduction

Presentation on immunogenicity and safety of JYNNEOS in 12-17 year olds  
EtR for JYNNEOS in outbreaks and due to the 2022 global outbreak

Dr. Faisal Minhaj (CDC/NCEZID)  
Dr. Buddy Creech (Vanderbilt University)  
Dr. Faisal Minhaj (CDC/NCEZID)  
Dr. Grace Marx (CDC/NCEZID)

#### **9:55 Lyme Disease Vaccine**

#### **10:00 Influenza Vaccines**

Introduction

Influenza vaccine effectiveness update

Dr. Jamie Loehr (ACIP, WG Chair)  
Dr. Aaron Frutos (CDC/NCIRD)  
Dr. Sophie Zhu (California DPH and CDC/PHIC), Dr.  
Joshua Quint (California DPH)  
Dr. Allyn Bandell (AstraZeneca)

FluMist self/caregiver administration

#### **11:15 Break**

#### **11:30 COVID-19 Vaccines**

Introduction

Moderna mRNA-1283 COVID-19 vaccine

Epidemiology and risk factors for COVID-19 hospitalizations

Vaccine effectiveness update

Workgroup considerations for use of 2025-2026 COVID-19 vaccines

Dr. Robert Schechter (ACIP, WG Chair)  
Dr. Bishoy Rizkalla (Moderna)  
Dr. Fiona Havers (CDC/NCIRD)  
Dr. Ruth Link-Gelles (CDC/NCIRD)  
Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)

#### **1:30 Pneumococcal Vaccines**

Workgroup Next Steps and Proposed Work Plan

Dr. Miwako Kobayashi (CDC/NCIRD)

#### **1:45 Break**

#### **2:00 Human Papillomavirus (HPV) Vaccines**

Introduction

Update on literature related to reduced number of doses for HPV vaccination

KEN SHE trial

HPV vaccination coverage

Modeling of reduced number of doses for HPV vaccination

Modified EtR: wording of the age for routine HPV vaccination

Workgroup next steps and considerations

Dr. Oliver Brooks (ACIP, WG Chair)  
Dr. Carla DeSisto (CDC/NCIRD)  
Dr. Ruanne Barnabas (Harvard University)  
Ms. Cassandra Pingali (CDC/NCIRD)  
Dr. Jane Kim (Harvard University)  
Dr. Ruth Stefanos (CDC/NCIRD)  
Dr. Lauri Markowitz (CDC/NCIRD)

#### **4:00 Cytomegalovirus (CMV) Vaccines**

Introduction

CMV and cCMV epidemiology and disease burden

CMV vaccine safety and immunogenicity data

Initial workgroup considerations for CMV vaccine policy

Dr. Denise Jamieson (ACIP, WG Chair)  
Dr. Tatiana Lanzieri (CDC/NCIRD)  
Dr. Robert Paris (Moderna)  
Dr. Tatiana Lanzieri (CDC/NCIRD)  
Dr. David Sugerman (CDC/NCIRD)

#### **5:00 U.S. Measles Update**

#### **5:30 Adjourn**

## Final Agenda

### Wednesday, April 16, 2025

#### **8:00 Welcome & Introductions**

#### **8:15 Meningococcal Vaccines**

Introduction

GSK pentavalent vaccine: update of EtR and workgroup considerations

Updates to Meningococcal vaccines VFC resolution

Introduction to MenQuadfi label change for infants

MenQuadfi in infants: safety and immunogenicity

Workgroup considerations regarding MenQuadfi in infants

**9:30**

*Break*

#### **9:45 Respiratory Syncytial Virus (RSV) Vaccines - Adults**

Introduction

Manufacturer Presentation: mRNA-1345 (Moderna) Immunogenicity in Adults 18-59 at Increased Risk; 24-Month Re-Vaccination

Manufacturer Presentation: Arexvy (GSK) 36-Month Re-Vaccination

Economic Analysis of Adult RSV Vaccination, including benefits and risk discussion

Comparison of Economic Analyses of Adult RSV Vaccination

Evidence to Recommendations

Clinical Considerations

**12:15**

*Break*

#### **12:30 Chikungunya Vaccines**

Introduction

EtR for use of virus-like particle chikungunya vaccine among adolescent and adult travelers

EtR for use of virus-like particle chikungunya vaccine among laboratory workers

Surveillance for adverse events following use of live attenuated chikungunya vaccine and its use among travelers

Clinical guidance for use of virus-like particle chikungunya vaccine among pregnant and breastfeeding women

**3:00**

*Break*

#### **3:10 Public Comment**

#### **3:40 VOTES**

Meningococcal Vaccines

Meningococcal Vaccines VFC

RSV Adult

Chikungunya Vaccines

#### **4:10 Respiratory Syncytial Virus (RSV) Immunizations- Maternal/Pediatric**

Introduction

EtR: Clesrovimab

Clinical considerations

#### **5:10 Adjourn**

Dr. Keipp Talbot (ACIP Chair)

Dr. Jamie Loehr (ACIP, WG Chair)

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Jeanne Santoli (CDC/NCIRD)

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Rachel Dawson (Sanofi)

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Albert Shaw (ACIP, WG Chair)

Dr. Frances Priddy (Moderna)

Dr. Susan Gerber (GSK)

Dr. Ismael Ortega-Sanchez (CDC/NCIRD)

Dr. Ismael Ortega-Sanchez (CDC/NCIRD)

Dr. Diya Surie (CDC/NCIRD), Dr. Michael Melgar (CDC/NCIRD)

Dr. Diya Surie (CDC/NCIRD)

Dr. Edwin Asturias (ACIP/WG Chair)

Dr. Susan Hills (CDC/NCEZID)

Dr. Erin Staples (CDC/NCEZID)

Dr. Susan Hills (CDC/NCEZID),

Dr. Erin Staples (CDC/NCEZID)

Dr. Susan Hills (CDC/NCEZID), Dr. Dana Meaney-Delman (CDC/NCBDDD)

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Jeanne Santoli (CDC/NCIRD)

Dr. Michael Melgar (CDC/NCIRD)

Dr. Susan Hills (CDC/NCEZID)

Dr. Helen Chu (ACIP, WG Chair)

Ms. Danielle Moulia (CDC/NCIRD)

Dr. Jefferson Jones (CDC/NCIRD)

Acronyms

|          |   |
|----------|---|
| cCMV     | Congenital cytomegalovirus                                      |
| CDC      | Centers for Disease Control and Prevention                      |
| CMV      | Cytomegalovirus   |
| COVID-19 | Coronavirus disease 2019  |
| DPH      | Department of Public Health                                     |
| EtR      | Evidence to Recommendations Framework                           |
| HPV      | Human papillomavirus  |
| NCBDDD   | National Center on Birth Defects and Developmental Disabilities |
| NCIRD    | National Center for Immunization & Respiratory Diseases         |
| NCEZID   | National Center for Emerging and Zoonotic Diseases              |
| PHIC     | Public Health Infrastructure Center                             |
| RSV      | Respiratory Syncytial Virus                                     |
| WG       | Work Group  |
| VFC      | Vaccines for Children   |